{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:49:36Z","timestamp":1792090176241,"version":"4.4.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,15]]},"DOI":"10.7759\/cureus.117975","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:02:51Z","timestamp":1792087371000},"source":"Crossref","is-referenced-by-count":0,"title":["Individualized and Platform-Designated Gene-Editing Studies in the Registered Clinical Record: A Case-by-Case Census Against 148 Eligible Studies"],"prefix":"10.7759","author":[{"given":"Oscar Mingtian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504747","article-title":"Patient-specific in vivo gene editing to treat a rare genetic disease","volume":"392","author":"Musunuru K","year":"2025","unstructured":"Musunuru K, Grandinette SA, Wang X, et al.. Patient-specific in vivo gene editing to treat a rare genetic disease. N Engl J Med. 2025, 392:2235-43. 10.1056\/NEJMoa2504747","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas P","year":"2014","unstructured":"Tebas P, Stein D, Tang WW, et al.. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014, 370:901-10. 10.1056\/NEJMoa1300662","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim W","year":"2017","unstructured":"Qasim W, Zhan H, Samarasinghe S, et al.. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017, 9:eaaj2013. 10.1126\/scitranslmed.aaj2013","journal-title":"Sci Transl Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul H","year":"2021","unstructured":"Frangoul H, Altshuler D, Cappellini MD, et al.. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med. 2021, 384:252-60. 10.1056\/NEJMoa2031054","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore JD","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, et al.. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021, 385:493-502. 10.1056\/NEJMoa2107454","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene editing for CEP290-associated retinal degeneration","volume":"390","author":"Pierce EA","year":"2024","unstructured":"Pierce EA, Aleman TS, Jayasundera KT, et al.. Gene editing for CEP290-associated retinal degeneration. N Engl J Med. 2024, 390:1972-84. 10.1056\/NEJMoa2309915","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2601283","article-title":"In vivo base editing of PCSK9 with VERVE-102 for hypercholesterolemia","volume":"395","author":"Vafai SB","year":"2026","unstructured":"Vafai SB, T\u00e4ubel J, Ashdown T, et al.. In vivo base editing of PCSK9 with VERVE-102 for hypercholesterolemia. N Engl J Med. 2026, 395:648-59. 10.1056\/NEJMoa2601283","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim J","year":"2019","unstructured":"Kim J, Hu C, Moufawad El Achkar C, et al.. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med. 2019, 381:1644-52. 10.1056\/NEJMoa1813279","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70515","article-title":"Making the impossible possible: baby KJ and the road map to personalized gene-editing care","volume":"15","author":"Almendro V","year":"2025","unstructured":"Almendro V, Kassim SH. Making the impossible possible: baby KJ and the road map to personalized gene-editing care. Clin Transl Med. 2025, 15:e70515. 10.1002\/ctm2.70515","journal-title":"Clin Transl Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2026.102892","article-title":"From one-size-fits-all to on-demand: personalized CRISPR gene editing for rare genetic liver diseases","volume":"50","author":"Quan AT","year":"2026","unstructured":"Quan AT. From one-size-fits-all to on-demand: personalized CRISPR gene editing for rare genetic liver diseases. Clin Res Hepatol Gastroenterol. 2026, 50:102892. 10.1016\/j.clinre.2026.102892","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone AV","year":"2019","unstructured":"Anzalone AV, Randolph PB, Davis JR, et al.. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019, 576:149-57. 10.1038\/s41586-019-1711-4","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone AV","year":"2020","unstructured":"Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020, 38:824-44. 10.1038\/s41587-020-0561-9","journal-title":"Nat Biotechnol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2026.103011","article-title":"The landscape and trajectory of global CRISPR therapeutics","volume":"37","author":"\u015eahin C","year":"2026","unstructured":"\u015eahin C, Formica TM, Silva A, et al.. The landscape and trajectory of global CRISPR therapeutics. Mol Ther Nucleic Acids. 2026, 37:103011. 10.1016\/j.omtn.2026.103011","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2026.102898","article-title":"A scoping review of gene editing in clinical trials: identifying aspects of trial design to accelerate clinical adoption","volume":"28","author":"Khare G","year":"2026","unstructured":"Khare G, Duong A, Hanotaux J, Shorr R, Nampoothiri RV, Maganti H, Allan DS. A scoping review of gene editing in clinical trials: identifying aspects of trial design to accelerate clinical adoption. Cytotherapy. 2026, 28:102898. 10.1016\/j.jcyt.2026.102898","journal-title":"Cytotherapy"},{"key":"ref15","unstructured":"21 U.S. Code \u00a7 356k - platform technologies. (2023). Accessed. September 18, 2026: https:\/\/www.law.cornell.edu\/uscode\/text\/21\/356k."},{"key":"ref16","unstructured":"Platform technology designation program for drug development guidance for industry. (2024). Accessed. September 18, 2026: https:\/\/www.fda.gov\/media\/178928\/download."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm E","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007, 4:e296. 10.1371\/journal.pmed.0040296","journal-title":"PLoS Med"},{"key":"ref18","unstructured":"ClinicalTrials.gov API. (2026). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/data-api\/api."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen J","year":"1960","unstructured":"Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960, 20:37-46. 10.1177\/001316446002000104","journal-title":"Educ Psychol Meas"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis JR","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977, 33:159-74. 10.2307\/2529310","journal-title":"Biometrics"},{"key":"ref21","unstructured":"Platform technology designation program for drug development. (2024). Accessed. September 18, 2026: https:\/\/www.asgct.org\/advocacy\/policy-statements\/platform-technology-designation-program-for-drug-development."},{"key":"ref22","unstructured":"FDA grants first platform technology designation to Sarepta's viral vector. (2025). Accessed. September 18, 2026: https:\/\/www.aabb.org\/news-resources\/news\/article\/2025\/06\/12\/fda-grants-first-platform-technology-designation-to-sarep...."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference","volume":"22","author":"Wilson EB","year":"1927","unstructured":"Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927, 22:209-12. 10.1080\/01621459.1927.10502953","journal-title":"J Am Stat Assoc"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1012065","article-title":"The ClinicalTrials.gov results database--update and key issues","volume":"364","author":"Zarin DA","year":"2011","unstructured":"Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database--update and key issues. N Engl J Med. 2011, 364:852-60. 10.1056\/NEJMsa1012065","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1409364","article-title":"Compliance with results reporting at ClinicalTrials.gov","volume":"372","author":"Anderson ML","year":"2015","unstructured":"Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. N Engl J Med. 2015, 372:1031-9. 10.1056\/NEJMsa1409364","journal-title":"N Engl J Med"},{"key":"ref26","unstructured":"Base editing hematopoietic stem cell and T cell gene therapy for CD40L-HyperIgM syndrome. single patient study. (2025). Accessed: September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT06959771."},{"key":"ref27","unstructured":"Treatment of a single patient with CRD-TMH-001. (2022). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT05514249."},{"key":"ref28","unstructured":"Clinical trial of the dual vector base editor for the treatment of the CHD3-R1025W mutation. (2025). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT06860672."},{"key":"ref29","unstructured":"Clinical study on the safety and efficacy of BRL-101 in the treatment of sickle cell disease. (2024). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT06287086."},{"key":"ref30","unstructured":"Engineered TILs\/CAR-TILs to treat advanced solid tumors. (2021). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT04842812."},{"key":"ref31","unstructured":"Study of LNP.UCD.ABE in patients with urea cycle disorders. (2026). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT07667387."},{"key":"ref32","unstructured":"Hematopoietic stem cell BCL11A enhancer gene editing for severe \u03b2-hemoglobinopathies. (2024). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT06647979."},{"key":"ref33","unstructured":"Base editing for mutation repair in hematopoietic stem & progenitor cells for X-linked chronic granulomatous disease. (2024). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT06325709."},{"key":"ref34","unstructured":"Ascending dose study of genome editing by zinc finger nuclease therapeutic SB-FIX in subjects with severe hemophilia B. (2016). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT02695160."},{"key":"ref35","unstructured":"A clinical study on the evaluation of BD114 for the treatment HPV-16-related cervical HSIL. (2025). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT07170254."},{"key":"ref36","unstructured":"Base-edited autologous hematopoietic stem cell transplantation in treating patients with \u03b2-thalassemia major. (2023). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT06065189."},{"key":"ref37","unstructured":"Rare tumor focused platform study of innovative therapies and technologies (PLATFORM2). (2025). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT07307053."},{"key":"ref38","unstructured":"NK510 cell therapy for refractory systemic lupus erythematosus. (2025). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT07083349."},{"key":"ref39","unstructured":"A safety and efficacy study evaluating CTX112 in subjects with refractory neurologic autoimmune disease (CRSP-AID-502). (2026). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT07804004."},{"key":"ref40","unstructured":"NY-ESO-1-redirected CRISPR (TCRendo and PD1) edited T cells (NYCE T cells). (2018). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT03399448."},{"key":"ref41","unstructured":"Long-term follow-up study of HIV-1 infected adults who received EBT-101. (2021). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT05143307."},{"key":"ref42","unstructured":"A safety and efficacy study evaluating CTX131 in adult subjects with relapsed or refractory solid tumors. (2023). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT05795595."},{"key":"ref43","unstructured":"A safety and efficacy study of TALEN and CRISPR\/Cas9 in the treatment of HPV-related cervical intraepithelial neoplasia I. (2017). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT03057912."},{"key":"ref44","unstructured":"A long-term follow-up study in participants who received CTX001. (2019). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT04208529."},{"key":"ref45","unstructured":"A safety and efficacy study evaluating CTX112 in adult subjects with refractory autoimmune disease. (2025). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT06925542."},{"key":"ref46","unstructured":"Autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases SB-728 for HIV (zinc-finger). (2009). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT00842634."},{"key":"ref47","unstructured":"Phase 1 dose escalation study of autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases in HIV-infected patients. (2010). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT01044654."},{"key":"ref48","unstructured":"Study of autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases in HIV-infected subjects. (2010). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT01252641."},{"key":"ref49","unstructured":"Dose escalation study of cyclophosphamide in HIV-infected subjects on HAART receiving SB-728-T. (2012). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT01543152."},{"key":"ref50","unstructured":"PD-1 knockout engineered T cells for advanced esophageal cancer. (2017). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT03081715."},{"key":"ref51","unstructured":"Repeat doses of SB-728mR-T after cyclophosphamide conditioning in HIV-infected subjects on HAART. (2014). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT02225665."},{"key":"ref52","unstructured":"PD-1 knockout engineered T cells for metastatic non-small cell lung cancer. (2016). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT02793856."},{"key":"ref53","unstructured":"A phase I study of T-cells genetically modified at the CCR5 gene by zinc finger nucleases SB-728mR in HIV-infected patients. (2015). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT02388594."},{"key":"ref54","unstructured":"PD1-CD19-CART in patients with r\/r B-cell lymphoma. (2019). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT04213469."},{"key":"ref55","unstructured":"Safety and efficacy of CRISPR\/Cas9 mRNA instantaneous gene editing therapy to treat refractory viral keratitis. (2020). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT04560790."},{"key":"ref56","unstructured":"PD-1 knockout anti-MUC1 CAR-T cells in the treatment of advanced breast cancer. (2023). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT05812326."},{"key":"ref57","unstructured":"A study to assess the safety, tolerability, and efficacy of ST-400 for treatment of transfusion-dependent beta-thalassemia (TDT). (2018). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT03432364."},{"key":"ref58","unstructured":"An open-label, FIH study evaluating the safety and tolerability of VCTX210A combination product in subjects with T1D. (2022). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT05210530."},{"key":"ref59","unstructured":"CCR5-modified CD4+ T cells for HIV infection (TRAILBLAZER). (2018). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT03666871."},{"key":"ref60","unstructured":"TT52CAR19 therapy for B-cell acute lymphoblastic leukaemia (B-ALL) (PBLTT52CAR19). (2020). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT04557436."},{"key":"ref61","unstructured":"Study of EBT-101 in Aviremic HIV-1 infected adults on stable ART. (2021). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT05144386."},{"key":"ref62","unstructured":"A study of VERVE-101 in patients with familial hypercholesterolemia and cardiovascular disease. (2022). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT05398029."},{"key":"ref63","unstructured":"A study of metastatic gastrointestinal cancers treated with tumor infiltrating lymphocytes in which the gene encoding the intracellular immune checkpoint CISH is inhibited using CRISPR genetic engineering. (2020). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT04426669."},{"key":"ref64","unstructured":"A clinical study evaluating the safety and efficacy of CS-101 in treating subjects with \u03b2-thalassemia. (2023). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT06024876."},{"key":"ref65","unstructured":"A safety and efficacy study evaluating CTX001 in subjects with severe sickle cell disease. (2018). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT03745287."},{"key":"ref66","unstructured":"A study to assess the safety, tolerability, and efficacy of BIVV003 for autologous hematopoietic stem cell transplantation in patients with severe sickle cell disease. (2018). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT03653247."},{"key":"ref67","unstructured":"Study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of NTLA-2001 in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and patients with transthyretin amyloidosis-related cardiomyopathy (ATTR-CM). (2020). Accessed. September 17, 2026: https:\/\/clinicaltrials.gov\/study\/NCT04601051."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/540221-individualized-and-platform-designated-gene-editing-studies-in-the-registered-clinical-record-a-case-by-case-census-against-148-eligible-studies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:02:57Z","timestamp":1792087377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/540221-individualized-and-platform-designated-gene-editing-studies-in-the-registered-clinical-record-a-case-by-case-census-against-148-eligible-studies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":67,"URL":"https:\/\/doi.org\/10.7759\/cureus.117975","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,15]]}}}